Articles by Liz Jones Hollis
Sanofi's ($SNY) Shantha buyout fails to live up to expectations
Sanofi-Aventis' ($SNY) acquisition of Indian vaccine maker Shantha Biotechnics has failed to live up to analyst forecasts, according to Bloomberg. Sanofi announced in July 2009 that it was paying
New vaccine offers hope in fight against pneumonia, meningtis
University of Leicester and Trinity College Dublin researchers have provided promising data in the fight against pneumonia, meningtis and septicaemia--and the discovery could lead to a new
CMS: Data shows moderate support for Provenge use
All of the available data for Dendreon's Provenge prostate cancer vaccine shows 'moderate' support for its use, according to a government analysis. CMS, which meets with outside advisers next
BiondVax looks to make mark in universal flu vax space
As we reported earlier, developing a universal flu vaccine is of great interest to many firms, with companies like BiondVax Pharmaceuticals and VaxInnate looking to make their marks in the field.
Discovery could show why cancer vaccines have failed
Cambridge researchers believe they have stumbled upon why scientists have struggled in using the immune system to fight tumors. New research has shown that a type of stromal cell found in many
Aaron Diamond team working on HIV vax
Aaron Diamond AIDS Research Center director and chief executive David Ho Da-i recently told a Hong Kong medical conference that his team is working on an HIV vaccine. And if everything goes well, Ho
Study: Support of mandatory HPV vaccine declines after negative news coverage
Laws mandating the HPV vaccine have aroused debate among parents, politicians, and medical and public health experts. And news coverage about such requirements tend to amplify this controversy,
GlobeImmune HCV vax shows promise in trial
GlobeImmune's GI-5005, the company's investigational Tarmogen product, improved sustained virologic response by 12 percent in patients with genotype 1 chronic hepatitis C virus infection who had
Sanofi dengue vax enters PhIII
Sanofi Pasteur's dengue vaccine has entered its first Phase III clinical study in Australia. The study is part of a global Phase III clinical study program aimed at advancing the development of a
Report: Higher income parents increasingly forgoing kids' vaccinations
Vaccination rates for children insured by commercial plans declined roughly four percentage points between 2008 and 2009. And experts fear that if this trend continues, the public's health could be
